About GeneNews Ltd (TSE:GEN)
GeneNews Limited is focused on developing and commercializing molecular diagnostic tests for early detection of diseases and for personalized health management, with a primary focus on cancer-related indications. The Company offers Sentinel Principle, which is a platform technology to detect virtually any disease or medical condition from a simple blood sample. The Company also offers ColonSentry, which is a blood-based test for assessing an individual's current risk of having colorectal cancer. The Company operates within the biotechnology, molecular diagnostic and genomic biomarker industry. The Company operates in Canada and the United States, and transacts business primarily with the United States partners and suppliers. The Company's subsidiaries include GeneNews Corporation and GeneNews Inc.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Medical Laboratories & Research
- Sub-Industry: N/A
- Symbol: TSE:GEN
- CUSIP: N/A
- Web: www.genenews.com/
- Market Cap: C$8.7 million
- Outstanding Shares: 96,663,000
- 50 Day Moving Avg: C$0.10
- 200 Day Moving Avg: C$0.18
- 52 Week Range: C$0.08 - C$0.53
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: $701,071.00
- Price / Sales: 12.41
- Book Value: C($0.05) per share
- Price / Book: -1.80
- EBITDA: ($4,600,000.00)
- Net Margins: -402.46%
- Return on Assets: -58.90%
- Average Volume: 273,857 shs.
Frequently Asked Questions for GeneNews Ltd (TSE:GEN)
What is GeneNews Ltd's stock symbol?
GeneNews Ltd trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GEN."
How were GeneNews Ltd's earnings last quarter?
GeneNews Ltd (TSE:GEN) announced its quarterly earnings results on Thursday, May, 15th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.02. The firm had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.04 million. View GeneNews Ltd's Earnings History.
When will GeneNews Ltd make its next earnings announcement?
Who are some of GeneNews Ltd's key competitors?
Some companies that are related to GeneNews Ltd include Delcath Systems (DCTH), Cytori Therapeutics (CYTX), Oxford Pharmascience Group Plc (OXP), Evgen Pharma PLC (EVG), Innovus Pharmaceuticals (INNV), Soligenix (SNGX), Xtant Medical Holdings (XTNT), Ampliphi Biosciences Corp (APHB), Synairgen plc (SNG), Concepta PLC (CPT), Proteome Sciences plc (PRM), Ixico Plc (IXI), Akers Biosciences (AKR), InspireMD (NSPR), ValiRx Plc (VAL), 3SBio (SSRX), Aegerion Pharmaceuticals (AEGR) and AEGON (AGN).
Who are GeneNews Ltd's key executives?
GeneNews Ltd's management team includes the folowing people:
- James R. Howard-Tripp, Executive Chairman of the Board
- Leslie Auld, Chief Financial Officer, Treasurer, Director
- Karl Wassmann, Executive Vice President - US Corporate Development
- Heinrich Dreismann Ph.D., Lead Director
- Harry A. Glorikian, Independent Director
- Garth A. C. MacRae, Independent Director
- Rory B. Riggs, Independent Director
How do I buy GeneNews Ltd stock?
Shares of GeneNews Ltd and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is GeneNews Ltd's stock price today?
MarketBeat Community Rating for GeneNews Ltd (TSE GEN)MarketBeat's community ratings are surveys of what our community members think about GeneNews Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of GeneNews Ltd stock can currently be purchased for approximately C$0.09.
Consensus Ratings for GeneNews Ltd (TSE:GEN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for GeneNews Ltd (TSE:GEN)
Analysts' Ratings History for GeneNews Ltd (TSE:GEN)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for GeneNews Ltd (TSE:GEN)Earnings History by Quarter for GeneNews Ltd (TSE GEN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/10/2017|| || || || || || || || |
|5/15/2014||C($0.04)||C($0.02)||C$0.04 million||C$0.20 million||View||N/A|
Earnings Estimates for GeneNews Ltd (TSE:GEN)
Current Year EPS Consensus Estimate: $-0.38 EPS
Dividend History for GeneNews Ltd (TSE:GEN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for GeneNews Ltd (TSE:GEN)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for GeneNews Ltd (TSE:GEN)
Latest Headlines for GeneNews Ltd (TSE:GEN)
GeneNews Ltd (GEN) Chart for Saturday, October, 21, 2017